GILEAD SCIENCES, INC. (GILD) stock intrinsic value fair value estimate & owner earnings analysis

Gilead Sciences is one franchise with a portfolio attached. HIV medicines were $20.8 billion of 2025 revenue of $29.4 billion, led by the once-daily tablet Biktarvy; the rest is liver disease (Epclusa, Vemlidy, Livdelzi), cell therapy (Yescarta, Tecartus), Trodelvy for breast cancer and the COVID antiviral Veklury. About 70% of sales are in the United States. EARNING POWER. Cash generation is far steadier than reported profit, which has swung between $0.1 billion and $8.5 billion because Gilead expenses purchased research immediately. After removing working-capital swings, stock-based pay and maintenance capital spending, owner earnings ran $5.79 to $9.98 a share from 2018 to 2025, median about $7.31. Adding back about $1 billion of yearly interest gives about $8.05 a share, roughly $10 billion a year before lenders are paid. We use 2018-2025 because that is today's HIV franchise with hepatitis C already normalized; 2016 was the tail of the hepatitis C boom and 2017 was distorted by the tax-reform accrual. 2025 was the best year at $9.98, up about 20%, but about $2.1 billion of it came from a swing in tax balances, so it is not treated as the new normal; the first forecast year grows only about 3%. THE KEY JUDGEMENT. Gilead's pipeline is largely bought. Acquisition cash (Kite, Immunomedics, CymaBay, and in 2026 Arcellx for its anito-cel cell therapy) leaves through investing activities, not operating cash flow, so cash flow alone overstates what owners keep. Purchases averaged about $3.5 billion a year in 2021-2025, and $11.3 billion went out in the first half of 2026. Every case below deducts a recurring business-development cost of $2.5 to $4 billion a year. Amortization of acquired products is added back, so the decay of those assets is carried in the declining earnings paths below. TWO DATES. A 2025 patent settlement means no US generic Biktarvy before April 1, 2036, more than two years later than previously expected. But in January 2026 Biktarvy was selected for Medicare price negotiation, with negotiated prices effective in 2028. The twice-yearly HIV prevention injection Yeztugo (lenacapavir), approved in 2025, is protected to 2037 but contributes little to the earnings record, so no growth from it is credited outside the bull case. BASE CASE ($52.83). Business cash flow of about $10.5-10.8 billion in 2026-27, stepping down to about $10 billion from 2028 as Medicare pricing bites, flat to 2035 because Gilead has a long record of replacing its own HIV regimens before they lose protection, then falling to about $7 billion after Biktarvy generics arrive in 2036. A business-development cost of $3.5 billion a year runs throughout. The business is worth about $85 billion. It owes $26.2 billion of bonds against $3.2 billion of cash. Most of the debt is fixed at roughly 3-4% for many years, well below today's long-term borrowing rates, which is worth about $3.5 billion, so net debt counts as about $19.6 billion. Equity is about $65.7 billion, or $52.83 per share. BEAR CASE ($17.16). Medicare and commercial price pressure take business cash flow down to about $8 billion by 2028 and $6.2 billion by 2035, the kind of price reset HIV and hepatitis C makers have already lived through. Biktarvy generics arrive on schedule in 2036, acquisitions keep failing at the 2022-2024 pace (about $6.9 billion of write-offs of bought research), and buying replacement products costs $4 billion a year. The business is worth about $41 billion against $19.6 billion of net debt, leaving about $21 billion of equity. Interest of about $1 billion stays covered throughout. BULL CASE ($94.66). Yeztugo and long-acting HIV treatment extend the franchise; business cash flow rises to about $12 billion by 2032 and settles near $9.5 billion after 2036, with a lower $2.5 billion business-development cost. The business is worth about $137 billion; equity about $118 billion. MARGIN OF SAFETY PRICE: $25. The earnings level is well documented, with eight straight years of $5.79 or more per share, so we are confident about where the business stands today. The worst plausible outcome is a Biktarvy price reset deeper than modeled combined with another expensive acquisition that fails; the balance sheet would survive it because the debt is long-dated, fixed-rate and covered many times by cash flow. The three things we are most likely to be wrong about are the depth of Medicare pricing, the cost of replacing Biktarvy, and whether Yeztugo becomes material. If all three go against us, the shares are worth roughly the bear case, high teens to low $20s, still well above zero. The business pays a dividend of $3.16 a share (about $4 billion a year), roughly 12-13% of a $25 price, which makes up much of the 20% target over the holding period. From $25 the bear outcome implies roughly that dividend with a modest decline in value, and a base outcome implies roughly double the price within a few years. Above about $25 the bear outcome no longer comfortably supports the target, so that is where we draw the line. CHANGES SINCE THE PREVIOUS ANALYSIS. The business facts are largely unchanged; the Arcellx purchase, completed in 2026, added to the debt. Earlier figures were built on a different basis and are not comparable.